Other Species / Isoforms
  VASP (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S2-p
______MsETVICsS
0 2
VASP (human) ______MsETVICsS S2-p
VASP (mouse) ______MsETVICSS S2-p
VASP (rat) ______MSNETVICS S2
S8-p
MsETVICsSRATVML
0 1
VASP (human) MsETVICsSRATVML S8-p
VASP (mouse) MsETVICSSRATVML S8
VASP (rat) SNETVICSSRATVML S9
Y16-p
SRATVMLyDDGNKRW
0 40
VASP (human) SRATVMLyDDGNKRW Y16-p
VASP (mouse) SRATVMLYDDSNKRW Y16
VASP (rat) SRATVMLYDDSNKRW Y17
Y39-p
AFSRVQIyHNPtANs
Upstream
1 1443
Putative in vivo kinases:
  • ALK (human)
Regulatory protein:
  • CSFR (human)
Treatment
  • ephrin_B1
  • siRNA
  • U0126
VASP (human) AFSRVQIyHNPtANs Y39-p
VASP (mouse) AFSRVQIyHNPtANS Y39-p
VASP (rat) AFSRVQIyHNPTANS Y40-p
T43-p
VQIyHNPtANsFRVV
0 9
VASP (human) VQIyHNPtANsFRVV T43-p
VASP (mouse) VQIyHNPtANSFRVV T43-p
VASP (rat) VQIyHNPTANSFRVV T44
S46-p
yHNPtANsFRVVGRk
0 2
VASP (human) yHNPtANsFRVVGRk S46-p
VASP (mouse) yHNPtANSFRVVGRK S46
VASP (rat) yHNPTANSFRVVGRK S47
K53-ac
sFRVVGRkMQPDQQV
0 1
VASP (human) sFRVVGRkMQPDQQV K53-ac
VASP (mouse) SFRVVGRKMQPDQQV K53
VASP (rat) SFRVVGRKLQPDQQV K54
R68-m1
VINCAIVrGVkYNQA
0 1
VASP (human) VINCAIVrGVkYNQA R68-m1
VASP (mouse) VINCAIIRGVKYNQA R68
VASP (rat) VINCAIIRGVKYNQA R69
K71-ub
CAIVrGVkYNQATPN
0 2
VASP (human) CAIVrGVkYNQATPN K71-ub
VASP (mouse) CAIIRGVKYNQATPI K71
VASP (rat) CAIIRGVKYNQATPI K72
S134-p
WSVPNGPsPEEVEQQ
0 1
VASP (human) WSVPNGPsPEEVEQQ S134-p
VASP (mouse) WSAQNGPSPEELEQQ S134
VASP (rat) WSTQNGPSPEELEQQ S135
S157-p
EHIERRVsNAGGPPA
Upstream
Downstream
43 3
VASP (human)
S157-p
VASP (mouse)
S153-p
VASP (rat)
S154-p
Effects on Modified Protein
  • activity, induced
  • intracellular localization
  • molecular association, regulation
Effects on Biological Processes:
  • cell adhesion, altered
  • cell growth, altered
  • cell motility, inhibited
  • cytoskeletal reorganization
  • transcription, inhibited
Kinase, in vitro:
  • PKACA (cow)
  • PKACA (human)
  • PKG1 (cow)
  • PKG1 (human)
  • PRKD1 (human)
Putative in vivo kinases:
  • PKACA (human)
  • PKCA (human)
  • PKG1 (human)
  • PRKD1 (human)
  • PRKD2 (human)
Regulatory protein:
  • ANPA (human)
  • PDE3A (human)
  • PKACA (cow)
  • PKG1 (human)
  • RAC1 (human)
  • RHOA (human)
Treatment
  • 5_6-DCl-cBIMPS
  • 8-Rp-cAMP
  • 8pCPT-cGMP
  • ACh
  • adenosine
  • ADP
  • alprostadil
  • ANP
  • atenolol
  • bacterial infection
  • bisindolylmaleimide
  • butoxamine
  • cAMP_analog
  • carbon_monoxide
  • CE-WIB801C
  • cGMP_analog
  • CID755673
  • colforsin
  • collagen
  • CRP
  • DEA-NONOate
  • dipyridamole
  • epoprostenol
  • glucose
  • Go_6976
  • H-89
  • H1152
  • H2O2
  • KT5720
  • KT5823
  • LDL_oxidized
  • linoleic_acid
  • low_glucose
  • microcystin-LR
  • NECA
  • nitric_oxide
  • nitrolinoleate
  • NKH_477
  • ODQ
  • okadaic_acid
  • phorbol_ester
  • PKI-(14-22)amide
  • PP2
  • racepinefrine
  • RGD
  • rottlerin
  • Rp-cAMPS
  • Rp-cGMP
  • siRNA
  • SNP
  • SR59230A
  • thrombin
  • U0126
  • virus infection
  • wortmannin
  • Y27632
VASP (human) EHIERRVsNAGGPPA S157-p
VASP (mouse) EHMERRVsNAGGPPA S153-p
VASP (rat) EHLERRVsNAGGPPA S154-p
S239-p
GAKLRKVsKQEEASG
Upstream
Downstream
47 29
VASP (human)
S239-p
VASP (mouse)
S235-p
Effects on Modified Protein
  • enzymatic activity, induced
  • intracellular localization
Effects on Biological Processes:
  • cell adhesion, altered
  • cell growth, altered
  • cell motility, altered
  • cytoskeletal reorganization
  • transcription, inhibited
Kinase, in vitro:
  • PKACA (cow)
  • PKACA (human)
  • PKG1 (cow)
  • PKG1 (human)
Putative in vivo kinases:
  • PKG1 (human)
  • PRKD2 (human)
Regulatory protein:
  • ANPA (human)
  • PKG1 (cow)
  • PKG1 (human)
  • PKG1 iso2 (human)
Treatment
  • 5_6-DCl-cBIMPS
  • 8-Rp-cAMP
  • ACh
  • ADP
  • alprostadil
  • ANP
  • argimesna
  • bacterial infection
  • cAMP_analog
  • carbon_monoxide
  • cGMP_analog
  • cholesterol
  • colforsin
  • CRP
  • DDTC
  • DEA-NONOate
  • dipyridamole
  • DT-2
  • EGF
  • epoprostenol
  • fMLP
  • GF109203X
  • glucose
  • glutamic acid
  • H-89
  • H2O2
  • H8
  • hyperlipidemia
  • IGF-1
  • irbesartan
  • KT5720
  • KT5823
  • L-NAME
  • L-NMMA
  • linoleic_acid
  • low_glucose
  • methyl-beta-cyclodextrin
  • N-nitro-L-arginine
  • nitric_oxide
  • nitrolinoleate
  • ODQ
  • PAR1-activating_peptide
  • phenylephrine
  • phorbol_ester
  • PKI-(14-22)amide
  • PP2
  • PP3
  • ristocetin
  • rottlerin
  • Rp-8pCPT-cGMPS
  • Rp-cAMPS
  • Rp-cGMP
  • scutellarin
  • SKI-1
  • SNAP
  • SNP
  • sphingosine_1-phosphate
  • SU6656
  • thrombin
  • U46619
  • VEGF
  • von_Willebrand_factor
VASP (human) GAKLRKVsKQEEASG S239-p
VASP (mouse) GAKLRKVsKQEEASG S235-p
VASP (rat) GAKLRKVsKEEASGG S236-p
T249-p
EEASGGPtAPkAESG
0 1
VASP (human) EEASGGPtAPkAESG T249-p
VASP (mouse) EEASGGPLAPKAENS L245
VASP (rat) EEASGGPLAPKAENS L245
K252-ac
SGGPtAPkAESGRsG
0 1
VASP (human) SGGPtAPkAESGRsG K252-ac
VASP (mouse) SGGPLAPKAENSRST K248
VASP (rat) SGGPLAPKAENSRGT K248
S258-p
PkAESGRsGGGGLME
0 2
VASP (human) PkAESGRsGGGGLME S258-p
VASP (mouse) PKAENSRSTGGGLME S254
VASP (rat) PKAENSRGTGGGLME G254
T278-p
LARRRKAtQVGEktP
Upstream
Downstream
9 22
Effects on Biological Processes:
  • carcinogenesis, altered
  • cell motility, altered
  • cytoskeletal reorganization
  • transcription, inhibited
Kinase, in vitro:
  • AMPKA1 (human)
  • p90RSK (human)
  • PKACA (human)
  • PKG1 (human)
Putative in vivo kinases:
  • p90RSK (human)
  • PKG1 (human)
Treatment
  • acadesine
  • bacterial infection
  • cGMP_analog
  • colforsin
  • compound_C
  • indirubin
  • KT5823
  • metformin
  • phenformin
  • rottlerin
  • serum
  • siRNA
VASP (human) LARRRKAtQVGEktP T278-p
VASP (mouse) LARRRKAtQVGEKPP T274-p
VASP (rat) LARRRKAtQVGEKPP T274-p
K283-ac
KAtQVGEktPkDEsA
0 3
VASP (human) KAtQVGEktPkDEsA K283-ac
VASP (mouse) KAtQVGEKPPKDEsA K279
VASP (rat) KAtQVGEKPPKDESA K279
T284-p
AtQVGEktPkDEsAN
Upstream
0 10
Treatment
  • ischemia
VASP (human) AtQVGEktPkDEsAN T284-p
VASP (mouse) AtQVGEKPPKDEsAS P280
VASP (rat) AtQVGEKPPKDESAS P280
K286-sm
QVGEktPkDEsANQE
0 1
VASP (human) QVGEktPkDEsANQE K286-sm
VASP (mouse) QVGEKPPKDEsASEE K282
VASP (rat) QVGEKPPKDESASQE K282
S289-p
EktPkDEsANQEEPE
0 4
VASP (human) EktPkDEsANQEEPE S289-p
VASP (mouse) EKPPKDEsASEESEA S285-p
VASP (rat) EKPPKDESASQEESE S285
S305-p
RVPAQSEsVRRPWEk
0 1
VASP (human) RVPAQSEsVRRPWEk S305-p
VASP (mouse) RLPAQSEPVRRPWEK P300
VASP (rat) RIPAQSEPVRRPWEK P301
K312-ub
sVRRPWEkNsTtLPR
0 1
VASP (human) sVRRPWEkNsTtLPR K312-ub
VASP (mouse) PVRRPWEKNSTtLPR K307
VASP (rat) PVRRPWEKNSTTLPR K308
S314-p
RRPWEkNsTtLPRMk
0 4
VASP (human) RRPWEkNsTtLPRMk S314-p
VASP (mouse) RRPWEKNSTtLPRMK S309
VASP (rat) RRPWEKNSTTLPRMK S310
T316-p
PWEkNsTtLPRMkss
Upstream
0 37
Treatment
  • nocodazole
VASP (human) PWEkNsTtLPRMkss T316-p
VASP (mouse) PWEKNSTtLPRMKss T311-p
VASP (rat) PWEKNSTTLPRMKsS T312
K321-m1
sTtLPRMkssssVtt
0 1
VASP (human) sTtLPRMkssssVtt K321-m1
VASP (mouse) STtLPRMKssssVtT K316
VASP (rat) STTLPRMKsSSsVTT K317
K321-ub
sTtLPRMkssssVtt
0 1
VASP (human) sTtLPRMkssssVtt K321-ub
VASP (mouse) STtLPRMKssssVtT K316
VASP (rat) STTLPRMKsSSsVTT K317
S322-p
TtLPRMkssssVttS
Upstream
Downstream
3 60
Effects on Modified Protein
  • intracellular localization
Effects on Biological Processes:
  • cell motility, inhibited
  • cytoskeletal reorganization
Kinase, in vitro:
  • PRKD1 (human)
Putative in vivo kinases:
  • PRKD1 (human)
  • PRKD2 (human)
Regulatory protein:
  • RHOA (human)
Treatment
  • CID755673
  • siRNA
VASP (human) TtLPRMkssssVttS S322-p
VASP (mouse) TtLPRMKssssVtTS S317-p
VASP (rat) TTLPRMKsSSsVTTS S318-p
S323-p
tLPRMkssssVttSE
0 20
VASP (human) tLPRMkssssVttSE S323-p
VASP (mouse) tLPRMKssssVtTSE S318-p
VASP (rat) TLPRMKsSSsVTTSE S319
S324-p
LPRMkssssVttSEt
0 20
VASP (human) LPRMkssssVttSEt S324-p
VASP (mouse) LPRMKssssVtTSEA S319-p
VASP (rat) LPRMKsSSsVTTSEA S320
S325-p
PRMkssssVttSEtQ
Upstream
0 26
Treatment
  • anti-CD3
VASP (human) PRMkssssVttSEtQ S325-p
VASP (mouse) PRMKssssVtTSEAH S320-p
VASP (rat) PRMKsSSsVTTSEAH S321-p
T327-p
MkssssVttSEtQPC
0 9
VASP (human) MkssssVttSEtQPC T327-p
VASP (mouse) MKssssVtTSEAHPs T322-p
VASP (rat) MKsSSsVTTSEAHPS T323
T328-p
kssssVttSEtQPCt
0 1
VASP (human) kssssVttSEtQPCt T328-p
VASP (mouse) KssssVtTSEAHPst T323
VASP (rat) KsSSsVTTSEAHPSV T324
T331-p
ssVttSEtQPCtPsS
0 1
VASP (human) ssVttSEtQPCtPsS T331-p
VASP (mouse) ssVtTSEAHPstPCS A326
VASP (rat) SsVTTSEAHPSVPSS A327
C334
ttSEtQPCtPsSSDy
0 1
VASP (human) ttSEtQPCtPsSSDy C334
VASP (mouse) tTSEAHPstPCSSDD S329-p
VASP (rat) TTSEAHPSVPSSSDD S330
T335-p
tSEtQPCtPsSSDyS
Upstream
0 52
Treatment
  • anti-CD3
  • ischemia
VASP (human) tSEtQPCtPsSSDyS T335-p
VASP (mouse) TSEAHPstPCSSDDS T330-p
VASP (rat) TSEAHPSVPSSSDDS V331
S337-p
EtQPCtPsSSDySDL
0 3
VASP (human) EtQPCtPsSSDySDL S337-p
VASP (mouse) EAHPstPCSSDDSDL C332
VASP (rat) EAHPSVPSSSDDSDL S333
Y341-p
CtPsSSDySDLQRVk
0 2
VASP (human) CtPsSSDySDLQRVk Y341-p
VASP (mouse) stPCSSDDSDLERVK D336
VASP (rat) SVPSSSDDSDLERVK D337
K348-ub
ySDLQRVkQELLEEV
0 1
VASP (human) ySDLQRVkQELLEEV K348-ub
VASP (mouse) DSDLERVKQELLEEV K343
VASP (rat) DSDLERVKQELVEEV K344
K363-ub
KKELQKVkEEIIEAF
0 2
VASP (human) KKELQKVkEEIIEAF K363-ub
VASP (mouse) RKELQKMKEEIIEVF K358
VASP (rat) RKELQKMKEEIIEVF K359